Global Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application (Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others), By Technology, By Regional Outlook and Forecast, 2022 - 2028

The Global Antibody Drug Conjugates Market size is expected to reach $13.8 billion by 2028, rising at a market growth of 14.2% CAGR during the forecast period.

Antibody Drug Conjugates (ADCs) are biopharmaceutical drugs that are particularly effective in the treatment of cancer. ADCs are designed to kill cancer cells while leaving healthy cells alone. Antibody-drug conjugates (ADCs) are a new class of anti-cancer medications that have been created in recent years. ADCs have shown to be a good substitute for conventional cancer treatments like chemotherapy or combination therapy because of their low off-target effects and significant cytotoxicity at tumor locations. Several advances in antibody-drug engineering have resulted in very effective tumor-targeting medicines with a broad therapeutic window. Two ADCs are already on the market such as Brentuximab vedotin and Trastuzumab emtansine, and many others are in clinical development. Enzymes in conjunction with prodrugs have proven to be a viable option. Horseradish peroxidase (HRP), a glyco-enzyme, has been shown to convert the hormone indole-3-acetic acid (IAA) into a highly effective cytotoxic poison. The utilization of this mixture of IAA and HRP in techniques like gene-directed enzyme prodrug treatment (GDEPT) and antibody-directed enzyme prodrug therapy (ADEPT) has been studied (ADEPT).

For instance, the market is likely to rise due to increased investment in this industry by key players like Pfizer Inc., Piramal Pharma Solution, F. Hoffman La-Roche, and Seagen, for the development of novel ADCs for cancer treatment. Additionally, for example, to meet the increased demand for commercial ADCs in the UK, CDMO Piramal Pharma Solutions (PPS) committed USD 74.4 million to the formation of two modern antibody-drug conjugates (ADC) production facilities at its present sites in Grangemouth, Scotland in February 2022.

Clinical trials are being conducted by the majority of corporations in order to move new products to market and to achieve label expansion for products that have previously been approved. Seagen, for example, began phase 1 clinical trials of two new antibody-drug conjugates, SGN-B7H4V and SGN-PDL1V, in patients with advanced solid cancers in January 2022. Additionally, the business, in conjunction with Astellas, finished patient recruitment for the cohort K EV-103 trial, which is used to treat First-Line Metastatic Urothelial Cancer (mUC). Market expansion is likely to be fueled by the satisfactory completion of the clinical trial research and future product approval.

COVID-19 Impact Analysis

With the overall COVID-19 pandemic, the expansion of many industries saw a decline in demand, however, several other areas remained untouched and showed promising indicators of future growth. COVID-19 impacted several businesses in different ways. As activities within hospitals and healthcare facilities were severely limited due to social distancing and lockdown measures enacted by governments around the world, the breakout of the COVID-19 pandemic had a massive impact on the antibody-drug conjugates business.

Market Growth Factors

The increasing cases of cancer

The rise in incidence of cancer within the population is a serious medical condition which is occurring due to various unknown reasons, and this have raised a substantial need of an advanced medical equipment to treat and cure various types of cancer diseases. Equipment in support is used extensively in companion diagnostics, customized pharmaceuticals, and other disease diagnostics, like illness risk assessment and drug research and development. The growing use of biomarkers in disease detection is one of the major factors anticipated to enhance antibody-drug conjugates market growth in the future years. The Lung and breast cancer are more existing cancers recorded since past few years.

Growing expenses in healthcare area in developing countries

Emerging country governments are increasing the expenditures in the healthcare sector. Governments around the world plan to enhance their health systems with this investment in order to deliver better and more modern solutions and minimize chronic disease cases. An ageing population, an increasing middle class, a growing proportion of lifestyle diseases, enhanced focus on public-private partnerships, fasten adoption of digital technologies, comprising of telemedicine, as well as enhanced investor interest and FDI inflows across the last two decades, are all boosting the growth of the healthcare infrastructure.

Marketing Restraining Factor:

Greater cost in the treatment of cancer

The exorbitant cost of cancer therapy is the most critical challenge facing the antibody-drug conjugates market. Prices for cancer medicines are rising in lockstep with their improving success rates. Cancer drugs can be expensive on a monthly basis, which the majority of people cannot manage. Even the wealthy, leave the poor or middle classes, struggle to bear the price of such costly therapies. The cost of medication may be multiple times what many people earn in a month. The rising price of cancer diagnosis and treatment in poor nations is another major impediment to the market's growth. Patients are increasingly selecting various low-cost detection techniques, which is limiting the number of patients who are examined for the concerned purpose.

Application Outlook

Based on Application, the market is segmented into Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others. The blood cancer segment garnered a significant revenue share in the antibody-drug conjugates market in 2021. Blood cancer is the fifth most frequent malignancy worldwide and the second main cause of death from cancer. For instance, as per the National Foundation for Cancer Research, 186,400 new instances of leukemia, lymphoma, and myeloma will be diagnosed in the United States in 2021. Additionally, several product approvals would benefit the market.

Technology Outlook

Based on Technology, the market is segmented into Cleavable Linker, Non-Cleavable Linker, and Others. The cleavable linkers segment acquired the highest revenue share in the antibody-drug conjugates market in 2021. Cleavable linkers are the most widely employed technology for an effective outcome of ADCs in cancer treatment because of the ability to stay stable in the bloodstream for longer periods of time and release a cytotoxin from ADCs.

Antibody Drug Conjugates Market Report Coverage

Report Attribute	Details
Market size value in 2021	USD 5.7 Billion
Market size forecast in 2028	USD 13.8 Billion
Base Year	2021
Historical Period	2018 to 2020
Forecast Period	2022 to 2028
Revenue Growth Rate	CAGR of 14.2% from 2022 to 2028
Number of Pages	188
Number of Tables	273
Report coverage	Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Companies Strategic Developments, Company Profiling
Segments covered	Technology, Application, Region
Country scope	US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers	The increasing cases of cancer Growing expenses in healthcare area in developing countries
Restraints	Greater cost in the treatment of cancer

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America emerged as the leading region in the antibody-drug conjugates market with the largest revenue share in 2021. The region's supremacy is due to well-established research facilities for the creation of novel ADCs, increasing per capita healthcare expenditure, and a rise in the prevalence of cancer. For instance, according to the American Cancer Society, cancer will affect 1.9 million people in the United States in 2022, resulting in 609,360 deaths. Market growth is likely to be fueled by the approval of new ADCs in the region. For example, the FDA authorized Tidvak in September 2021 for the treatment of adult patients with recurrent cervical or metastatic cancer.

Free Valuable Insights: Global Antibody Drug Conjugates Market size to reach USD 13.8 Billion by 2028

KBV Cardinal Matrix - Antibody Drug Conjugates Market Competition Analysis

The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; F. Hoffmann-La Roche Ltd. and Pfizer, Inc. are the forerunners in the Antibody Drug Conjugates Market. Companies such as GlaxoSmithKline plc, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited are some of the key innovators in the Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Seagen, Inc., ADC Therapeutics SA, and Daiichi Sankyo Company, Limited.

Recent Strategies Deployed in Antibody Drug Conjugates Market

» Partnerships, Collaborations and Agreements:

• Mar-2022: Seagen joined hands with Sanofi, a French multinational healthcare company. This collaboration aimed to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets and use Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology.
• Jan-2022: Pfizer signed a research collaboration and license agreement with Dren Bio, a biopharmaceutical company, a developer of therapeutic antibodies for the treatment of cancer. This agreement aimed to concentrate on the discovery and development of therapeutic bispecific antibodies for select oncology targets utilizing Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform.
• Jan-2022: Gilead Sciences joined hands with Merck, a German multinational science and technology company. This collaboration aimed to analyze the integration of Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in first-line metastatic non-small cell lung cancer (NSCLC) and Gilead’s Trop-2 targeting antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy). Under this collaboration, Merck would sponsor a global Phase 3 clinical trial of Trodelvy in unification with KEYTRUDA as a first-line treatment for patients with metastatic NSCLC.
• Aug-2021: Seagen entered into an agreement with RemeGen, a leading innovative biopharmaceutical company based in China. This agreement aimed to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC and maximize the potential of disitamab vedotin.
• Jun-2021: GlaxoSmithKline entered into an agreement with iTeos Therapeutics, a clinical-stage biopharmaceutical company. This agreement aimed to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody presently in phase I development as a potential treatment for patients with cancer.
• Mar-2021: Pfizer signed a worldwide license agreement with Pyxis Oncology, a preclinical oncology company. This agreement aimed to develop and commercialize two antibody-drug conjugates (ADC) candidates and a license to Pfizer’s ADC technology platform, also allowing expansion of the ADC portfolio and strengthening the developmental capabilities, and demonstrating successful implementation of overarching corporate strategy to align in-house organic growth with strategic in-licensing and partnerships to develop the multi-asset multi-platform portfolio.
• Nov-2020: AstraZeneca joined hands with Fusion Pharmaceuticals, a clinical-stage oncology company dedicated to developing next-generation radiopharmaceuticals as accurate medicines. This collaboration aimed to create and commercialize next-generation alpha-emitting radiopharmaceuticals and unification therapies for the treatment of cancer.
• Sep-2020: Seagen joined hands with Merck, a German multinational science and technology company. This collaboration aimed to start a wide joint development program evaluating ladiratuzumab vedotin as monotherapy and in integration with Merck’s anti-PD-1 therapy KEYTRUDA in hormone receptor-positive breast cancer, triple-negative breast cancer, and other LIV-1-expressing solid tumors.
• Jul-2020: AstraZeneca came into an agreement with Daiichi Sankyo Company, a global pharmaceutical company. This agreement aimed to receive potential new medicine for the treatment of many tumor types, DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC).
• Jul-2020: Daiichi Sankyo Company joined hands with Gustave Roussy, the first leader cancer-research hospital in Europe. This collaboration aimed to enhance and allow the development of patritumab deruxtecan (U3-1402) and DS-1062, two of Daiichi Sankyo’s lead DXd antibody drugs conjugates (ADCs), in lung and breast cancer. 
• Jul-2020: F. Hoffman-La Roche joined hands with Immunomedics, a biotechnology company. This collaboration aimed to extend the clinical trial collaboration to analyze sacituzumab govitecan-hziy (Trodelvy), a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) also Roche would be conducting two open-label, multicenter, randomized Phase Ib/II studies utilizing its MORPHEUS platform.
• Jun-2020: GlaxoSmithKline came into a partnership with IDEAYA Biosciences, a synthetic lethality-focused precision medicine oncology company. This partnership aimed to comprise IDEAYA’s Synthetic Lethality programs MAT2A, Pol Theta, and Werner Helicase programs anticipated to reach clinical trials in the next three years.

» Acquisitions and Mergers:

• Jan-2022: Takeda Pharmaceutical took over Adaptate Biotherapeutics, a UK company focused on developing antibody-based therapeutics. This acquisition aimed for Takeda to gather Adaptate’s antibody-based γδ T cell engager platform, comprising pre-clinical candidate and discovery pipeline programs.
• Oct-2020: Gilead Sciences took over Immunomedics, a Morris Plains, New Jersey-based clinical-stage biopharmaceutical company dedicated to antibody-drug conjugates (ADCs). This acquisition aimed to deliver Gilead with Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted fastened approval by the U.S. Food and Drug Administration (FDA) in April for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) that received minimum two prior therapies for metastatic disease.

» Approvals and Trials:

• Aug-2021: GlaxoSmithKline received approval from US Food and Drug Administration (FDA) for a new indication for JEMPERLI (dostarlimab-gxly), a programmed cell death receptor-1 (PD-1) blocking antibody. This approval aimed to provide treatment to adult patients with mismatch repair-deficient (dMMR) repetitive or advanced solid tumors, as ascertained by an FDA-approved test, that has progressed on or following before treatment that has no satisfactory substitute treatment options.
• Sep-2021: Astellas Pharma and Seagen received approval from Japan's Ministry of Health, Labour, and Welfare (MHLW) for PADCEV (enfortumab vedotin). This approval aimed at radically unresectable urothelial carcinoma that progressed post-anti-cancer chemotherepy.
• Apr-2021: ADC Therapeutics received approval from US Food and Drug Administration (FDA) for ADC Therapeutics’ ZYNLONTA, as a third-line therapy for patients with relapsed or refractory (r/r) difuse large Bcell lymphoma (DLBCL). This approval aimed to include patients with DLBCL developing from high-grade B-cell lymphoma and low-grade lymphoma. 

Scope of the Study

Market Segments Covered in the Report:

By Application

• Breast Cancer
• Blood Cancer
• Urothelial Cancer & Bladder Cancer
• Others

By Technology

• Cleavable Linker
• Non-Cleavable Linker
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Takeda Pharmaceutical Company Limited
• Hoffmann-La Roche Ltd.
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Pfizer, Inc.
• Astellas Pharma, Inc.
• Gilead Sciences, Inc.
• Seagen, Inc.
• ADC Therapeutics SA
• Daiichi Sankyo Company, Limited

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Antibody Drug Conjugates Market, by Application
1.4.2 Global Antibody Drug Conjugates Market, by Technology
1.4.3 Global Antibody Drug Conjugates Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition & mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players

Chapter 4. Global Antibody Drug Conjugates Market by Application
4.1 Global Breast Cancer Market by Region
4.2 Global Blood Cancer Market by Region
4.3 Global Urothelial Cancer & Bladder Cancer Market by Region
4.4 Global Others Market by Region

Chapter 5. Global Antibody Drug Conjugates Market by Technology
5.1 Global Cleavable Linker Market by Region
5.2 Global Non-Cleavable Linker Market by Region
5.3 Global Others Market by Region

Chapter 6. Global Antibody Drug Conjugates Market by Region
6.1 North America Antibody Drug Conjugates Market
6.1.1 North America Antibody Drug Conjugates Market by Application
6.1.1.1 North America Breast Cancer Market by Country
6.1.1.2 North America Blood Cancer Market by Country
6.1.1.3 North America Urothelial Cancer & Bladder Cancer Market by Country
6.1.1.4 North America Others Market by Country
6.1.2 North America Antibody Drug Conjugates Market by Technology
6.1.2.1 North America Cleavable Linker Market by Country
6.1.2.2 North America Non-Cleavable Linker Market by Country
6.1.2.3 North America Others Market by Country
6.1.3 North America Antibody Drug Conjugates Market by Country
6.1.3.1 US Antibody Drug Conjugates Market
6.1.3.1.1 US Antibody Drug Conjugates Market by Application
6.1.3.1.2 US Antibody Drug Conjugates Market by Technology
6.1.3.2 Canada Antibody Drug Conjugates Market
6.1.3.2.1 Canada Antibody Drug Conjugates Market by Application
6.1.3.2.2 Canada Antibody Drug Conjugates Market by Technology
6.1.3.3 Mexico Antibody Drug Conjugates Market
6.1.3.3.1 Mexico Antibody Drug Conjugates Market by Application
6.1.3.3.2 Mexico Antibody Drug Conjugates Market by Technology
6.1.3.4 Rest of North America Antibody Drug Conjugates Market
6.1.3.4.1 Rest of North America Antibody Drug Conjugates Market by Application
6.1.3.4.2 Rest of North America Antibody Drug Conjugates Market by Technology
6.2 Europe Antibody Drug Conjugates Market
6.2.1 Europe Antibody Drug Conjugates Market by Application
6.2.1.1 Europe Breast Cancer Market by Country
6.2.1.2 Europe Blood Cancer Market by Country
6.2.1.3 Europe Urothelial Cancer & Bladder Cancer Market by Country
6.2.1.4 Europe Others Market by Country
6.2.2 Europe Antibody Drug Conjugates Market by Technology
6.2.2.1 Europe Cleavable Linker Market by Country
6.2.2.2 Europe Non-Cleavable Linker Market by Country
6.2.2.3 Europe Others Market by Country
6.2.3 Europe Antibody Drug Conjugates Market by Country
6.2.3.1 Germany Antibody Drug Conjugates Market
6.2.3.1.1 Germany Antibody Drug Conjugates Market by Application
6.2.3.1.2 Germany Antibody Drug Conjugates Market by Technology
6.2.3.2 UK Antibody Drug Conjugates Market
6.2.3.2.1 UK Antibody Drug Conjugates Market by Application
6.2.3.2.2 UK Antibody Drug Conjugates Market by Technology
6.2.3.3 France Antibody Drug Conjugates Market
6.2.3.3.1 France Antibody Drug Conjugates Market by Application
6.2.3.3.2 France Antibody Drug Conjugates Market by Technology
6.2.3.4 Russia Antibody Drug Conjugates Market
6.2.3.4.1 Russia Antibody Drug Conjugates Market by Application
6.2.3.4.2 Russia Antibody Drug Conjugates Market by Technology
6.2.3.5 Spain Antibody Drug Conjugates Market
6.2.3.5.1 Spain Antibody Drug Conjugates Market by Application
6.2.3.5.2 Spain Antibody Drug Conjugates Market by Technology
6.2.3.6 Italy Antibody Drug Conjugates Market
6.2.3.6.1 Italy Antibody Drug Conjugates Market by Application
6.2.3.6.2 Italy Antibody Drug Conjugates Market by Technology
6.2.3.7 Rest of Europe Antibody Drug Conjugates Market
6.2.3.7.1 Rest of Europe Antibody Drug Conjugates Market by Application
6.2.3.7.2 Rest of Europe Antibody Drug Conjugates Market by Technology
6.3 Asia Pacific Antibody Drug Conjugates Market
6.3.1 Asia Pacific Antibody Drug Conjugates Market by Application
6.3.1.1 Asia Pacific Breast Cancer Market by Country
6.3.1.2 Asia Pacific Blood Cancer Market by Country
6.3.1.3 Asia Pacific Urothelial Cancer & Bladder Cancer Market by Country
6.3.1.4 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Antibody Drug Conjugates Market by Technology
6.3.2.1 Asia Pacific Cleavable Linker Market by Country
6.3.2.2 Asia Pacific Non-Cleavable Linker Market by Country
6.3.2.3 Asia Pacific Others Market by Country
6.3.3 Asia Pacific Antibody Drug Conjugates Market by Country
6.3.3.1 China Antibody Drug Conjugates Market
6.3.3.1.1 China Antibody Drug Conjugates Market by Application
6.3.3.1.2 China Antibody Drug Conjugates Market by Technology
6.3.3.2 Japan Antibody Drug Conjugates Market
6.3.3.2.1 Japan Antibody Drug Conjugates Market by Application
6.3.3.2.2 Japan Antibody Drug Conjugates Market by Technology
6.3.3.3 India Antibody Drug Conjugates Market
6.3.3.3.1 India Antibody Drug Conjugates Market by Application
6.3.3.3.2 India Antibody Drug Conjugates Market by Technology
6.3.3.4 South Korea Antibody Drug Conjugates Market
6.3.3.4.1 South Korea Antibody Drug Conjugates Market by Application
6.3.3.4.2 South Korea Antibody Drug Conjugates Market by Technology
6.3.3.5 Singapore Antibody Drug Conjugates Market
6.3.3.5.1 Singapore Antibody Drug Conjugates Market by Application
6.3.3.5.2 Singapore Antibody Drug Conjugates Market by Technology
6.3.3.6 Malaysia Antibody Drug Conjugates Market
6.3.3.6.1 Malaysia Antibody Drug Conjugates Market by Application
6.3.3.6.2 Malaysia Antibody Drug Conjugates Market by Technology
6.3.3.7 Rest of Asia Pacific Antibody Drug Conjugates Market
6.3.3.7.1 Rest of Asia Pacific Antibody Drug Conjugates Market by Application
6.3.3.7.2 Rest of Asia Pacific Antibody Drug Conjugates Market by Technology
6.4 LAMEA Antibody Drug Conjugates Market
6.4.1 LAMEA Antibody Drug Conjugates Market by Application
6.4.1.1 LAMEA Breast Cancer Market by Country
6.4.1.2 LAMEA Blood Cancer Market by Country
6.4.1.3 LAMEA Urothelial Cancer & Bladder Cancer Market by Country
6.4.1.4 LAMEA Others Market by Country
6.4.2 LAMEA Antibody Drug Conjugates Market by Technology
6.4.2.1 LAMEA Cleavable Linker Market by Country
6.4.2.2 LAMEA Non-Cleavable Linker Market by Country
6.4.2.3 LAMEA Others Market by Country
6.4.3 LAMEA Antibody Drug Conjugates Market by Country
6.4.3.1 Brazil Antibody Drug Conjugates Market
6.4.3.1.1 Brazil Antibody Drug Conjugates Market by Application
6.4.3.1.2 Brazil Antibody Drug Conjugates Market by Technology
6.4.3.2 Argentina Antibody Drug Conjugates Market
6.4.3.2.1 Argentina Antibody Drug Conjugates Market by Application
6.4.3.2.2 Argentina Antibody Drug Conjugates Market by Technology
6.4.3.3 UAE Antibody Drug Conjugates Market
6.4.3.3.1 UAE Antibody Drug Conjugates Market by Application
6.4.3.3.2 UAE Antibody Drug Conjugates Market by Technology
6.4.3.4 Saudi Arabia Antibody Drug Conjugates Market
6.4.3.4.1 Saudi Arabia Antibody Drug Conjugates Market by Application
6.4.3.4.2 Saudi Arabia Antibody Drug Conjugates Market by Technology
6.4.3.5 South Africa Antibody Drug Conjugates Market
6.4.3.5.1 South Africa Antibody Drug Conjugates Market by Application
6.4.3.5.2 South Africa Antibody Drug Conjugates Market by Technology
6.4.3.6 Nigeria Antibody Drug Conjugates Market
6.4.3.6.1 Nigeria Antibody Drug Conjugates Market by Application
6.4.3.6.2 Nigeria Antibody Drug Conjugates Market by Technology
6.4.3.7 Rest of LAMEA Antibody Drug Conjugates Market
6.4.3.7.1 Rest of LAMEA Antibody Drug Conjugates Market by Application
6.4.3.7.2 Rest of LAMEA Antibody Drug Conjugates Market by Technology

Chapter 7. Company Profiles
7.1 Takeda Pharmaceutical Company Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.1 Recent strategies and developments:
7.1.1.1 Partnerships, Collaborations, and Agreements:
7.1.1.2 Acquisitions and Mergers:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 AstraZeneca PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 GlaxoSmithKline PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations and Agreements:
7.6 Astellas Pharma, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Approvals and Trials:
7.7 Gilead Sciences, Inc.
7.7.1 Company overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent strategies and developments:
7.7.4.1 Acquisitions and Mergers:
7.7.4.2 Partnerships, Collaborations and Agreements:
7.8 Seagen, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.8.4 Recent strategies and developments:
7.8.4.1 Partnerships, Collaborations, and Agreements:
7.9 ADC Therapeutics SA
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expenses
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Approvals and Trials:
7.10. Daiichi Sankyo Company, Limited
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expense
7.10.4 Recent strategies and developments:
7.10.4.1 Partnerships, Collaborations, and Agreements:

TABLE 1 Global Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 2 Global Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Antibody Drug Conjugates Market
TABLE 4 Acquisition & mergers – Antibody Drug Conjugates Market
TABLE 5 Approvals and trials– Antibody Drug Conjugates Market
TABLE 6 Global Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 7 Global Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 8 Global Breast Cancer Market by Region, 2018 - 2021, USD Million
TABLE 9 Global Breast Cancer Market by Region, 2022 - 2028, USD Million
TABLE 10 Global Blood Cancer Market by Region, 2018 - 2021, USD Million
TABLE 11 Global Blood Cancer Market by Region, 2022 - 2028, USD Million
TABLE 12 Global Urothelial Cancer & Bladder Cancer Market by Region, 2018 - 2021, USD Million
TABLE 13 Global Urothelial Cancer & Bladder Cancer Market by Region, 2022 - 2028, USD Million
TABLE 14 Global Others Market by Region, 2018 - 2021, USD Million
TABLE 15 Global Others Market by Region, 2022 - 2028, USD Million
TABLE 16 Global Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 17 Global Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 18 Global Cleavable Linker Market by Region, 2018 - 2021, USD Million
TABLE 19 Global Cleavable Linker Market by Region, 2022 - 2028, USD Million
TABLE 20 Global Non-Cleavable Linker Market by Region, 2018 - 2021, USD Million
TABLE 21 Global Non-Cleavable Linker Market by Region, 2022 - 2028, USD Million
TABLE 22 Global Others Market by Region, 2018 - 2021, USD Million
TABLE 23 Global Others Market by Region, 2022 - 2028, USD Million
TABLE 24 Global Antibody Drug Conjugates Market by Region, 2018 - 2021, USD Million
TABLE 25 Global Antibody Drug Conjugates Market by Region, 2022 - 2028, USD Million
TABLE 26 North America Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 27 North America Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 28 North America Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 29 North America Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 30 North America Breast Cancer Market by Country, 2018 - 2021, USD Million
TABLE 31 North America Breast Cancer Market by Country, 2022 - 2028, USD Million
TABLE 32 North America Blood Cancer Market by Country, 2018 - 2021, USD Million
TABLE 33 North America Blood Cancer Market by Country, 2022 - 2028, USD Million
TABLE 34 North America Urothelial Cancer & Bladder Cancer Market by Country, 2018 - 2021, USD Million
TABLE 35 North America Urothelial Cancer & Bladder Cancer Market by Country, 2022 - 2028, USD Million
TABLE 36 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 37 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 38 North America Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 39 North America Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 40 North America Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 41 North America Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 42 North America Non-Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 43 North America Non-Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 44 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 45 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 46 North America Antibody Drug Conjugates Market by Country, 2018 - 2021, USD Million
TABLE 47 North America Antibody Drug Conjugates Market by Country, 2022 - 2028, USD Million
TABLE 48 US Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 49 US Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 50 US Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 51 US Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 52 US Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 53 US Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 54 Canada Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 55 Canada Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 56 Canada Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 57 Canada Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 58 Canada Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 59 Canada Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 60 Mexico Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 61 Mexico Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 62 Mexico Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 63 Mexico Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 64 Mexico Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 65 Mexico Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 66 Rest of North America Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 67 Rest of North America Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 68 Rest of North America Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 69 Rest of North America Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 70 Rest of North America Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 71 Rest of North America Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 72 Europe Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 73 Europe Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 74 Europe Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 75 Europe Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 76 Europe Breast Cancer Market by Country, 2018 - 2021, USD Million
TABLE 77 Europe Breast Cancer Market by Country, 2022 - 2028, USD Million
TABLE 78 Europe Blood Cancer Market by Country, 2018 - 2021, USD Million
TABLE 79 Europe Blood Cancer Market by Country, 2022 - 2028, USD Million
TABLE 80 Europe Urothelial Cancer & Bladder Cancer Market by Country, 2018 - 2021, USD Million
TABLE 81 Europe Urothelial Cancer & Bladder Cancer Market by Country, 2022 - 2028, USD Million
TABLE 82 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 83 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 84 Europe Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 85 Europe Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 86 Europe Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 87 Europe Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 88 Europe Non-Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 89 Europe Non-Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 90 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 91 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 92 Europe Antibody Drug Conjugates Market by Country, 2018 - 2021, USD Million
TABLE 93 Europe Antibody Drug Conjugates Market by Country, 2022 - 2028, USD Million
TABLE 94 Germany Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 95 Germany Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 96 Germany Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 97 Germany Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 98 Germany Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 99 Germany Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 100 UK Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 101 UK Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 102 UK Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 103 UK Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 104 UK Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 105 UK Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 106 France Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 107 France Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 108 France Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 109 France Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 110 France Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 111 France Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 112 Russia Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 113 Russia Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 114 Russia Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 115 Russia Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 116 Russia Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 117 Russia Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 118 Spain Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 119 Spain Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 120 Spain Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 121 Spain Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 122 Spain Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 123 Spain Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 124 Italy Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 125 Italy Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 126 Italy Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 127 Italy Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 128 Italy Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 129 Italy Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 130 Rest of Europe Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 131 Rest of Europe Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 132 Rest of Europe Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 133 Rest of Europe Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 134 Rest of Europe Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 135 Rest of Europe Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 136 Asia Pacific Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 137 Asia Pacific Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 138 Asia Pacific Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 139 Asia Pacific Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 140 Asia Pacific Breast Cancer Market by Country, 2018 - 2021, USD Million
TABLE 141 Asia Pacific Breast Cancer Market by Country, 2022 - 2028, USD Million
TABLE 142 Asia Pacific Blood Cancer Market by Country, 2018 - 2021, USD Million
TABLE 143 Asia Pacific Blood Cancer Market by Country, 2022 - 2028, USD Million
TABLE 144 Asia Pacific Urothelial Cancer & Bladder Cancer Market by Country, 2018 - 2021, USD Million
TABLE 145 Asia Pacific Urothelial Cancer & Bladder Cancer Market by Country, 2022 - 2028, USD Million
TABLE 146 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 147 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 148 Asia Pacific Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 149 Asia Pacific Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 150 Asia Pacific Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 151 Asia Pacific Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 152 Asia Pacific Non-Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 153 Asia Pacific Non-Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 154 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 155 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 156 Asia Pacific Antibody Drug Conjugates Market by Country, 2018 - 2021, USD Million
TABLE 157 Asia Pacific Antibody Drug Conjugates Market by Country, 2022 - 2028, USD Million
TABLE 158 China Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 159 China Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 160 China Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 161 China Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 162 China Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 163 China Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 164 Japan Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 165 Japan Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 166 Japan Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 167 Japan Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 168 Japan Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 169 Japan Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 170 India Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 171 India Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 172 India Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 173 India Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 174 India Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 175 India Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 176 South Korea Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 177 South Korea Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 178 South Korea Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 179 South Korea Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 180 South Korea Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 181 South Korea Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 182 Singapore Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 183 Singapore Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 184 Singapore Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 185 Singapore Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 186 Singapore Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 187 Singapore Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 188 Malaysia Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 189 Malaysia Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 190 Malaysia Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 191 Malaysia Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 192 Malaysia Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 193 Malaysia Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 194 Rest of Asia Pacific Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 195 Rest of Asia Pacific Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 196 Rest of Asia Pacific Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 197 Rest of Asia Pacific Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 198 Rest of Asia Pacific Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 199 Rest of Asia Pacific Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million9
TABLE 200 LAMEA Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 201 LAMEA Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 202 LAMEA Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 203 LAMEA Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 204 LAMEA Breast Cancer Market by Country, 2018 - 2021, USD Million
TABLE 205 LAMEA Breast Cancer Market by Country, 2022 - 2028, USD Million
TABLE 206 LAMEA Blood Cancer Market by Country, 2018 - 2021, USD Million
TABLE 207 LAMEA Blood Cancer Market by Country, 2022 - 2028, USD Million
TABLE 208 LAMEA Urothelial Cancer & Bladder Cancer Market by Country, 2018 - 2021, USD Million
TABLE 209 LAMEA Urothelial Cancer & Bladder Cancer Market by Country, 2022 - 2028, USD Million
TABLE 210 LAMEA Others Market by Country, 2018 - 2021, USD Million
TABLE 211 LAMEA Others Market by Country, 2022 - 2028, USD Million
TABLE 212 LAMEA Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 213 LAMEA Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 214 LAMEA Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 215 LAMEA Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 216 LAMEA Non-Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 217 LAMEA Non-Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 218 LAMEA Others Market by Country, 2018 - 2021, USD Million
TABLE 219 LAMEA Others Market by Country, 2022 - 2028, USD Million
TABLE 220 LAMEA Antibody Drug Conjugates Market by Country, 2018 - 2021, USD Million
TABLE 221 LAMEA Antibody Drug Conjugates Market by Country, 2022 - 2028, USD Million
TABLE 222 Brazil Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 223 Brazil Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 224 Brazil Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 225 Brazil Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 226 Brazil Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 227 Brazil Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 228 Argentina Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 229 Argentina Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 230 Argentina Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 231 Argentina Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 232 Argentina Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 233 Argentina Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 234 UAE Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 235 UAE Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 236 UAE Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 237 UAE Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 238 UAE Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 239 UAE Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 240 Saudi Arabia Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 241 Saudi Arabia Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 242 Saudi Arabia Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 243 Saudi Arabia Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 244 Saudi Arabia Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 245 Saudi Arabia Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 246 South Africa Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 247 South Africa Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 248 South Africa Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 249 South Africa Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 250 South Africa Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 251 South Africa Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 252 Nigeria Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 253 Nigeria Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 254 Nigeria Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 255 Nigeria Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 256 Nigeria Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 257 Nigeria Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 258 Rest of LAMEA Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 259 Rest of LAMEA Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 260 Rest of LAMEA Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 261 Rest of LAMEA Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 262 Rest of LAMEA Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 263 Rest of LAMEA Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 264 Key Information – Takeda Pharmaceutical Company Limited
TABLE 265 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 266 KEY INFORMATION – ASTRAZENECA PLC
TABLE 267 Key Information – GlaxoSmithKline PLC
TABLE 268 Key Information – Pfizer, Inc.
TABLE 269 key information – Astellas Pharma, Inc.
TABLE 270 Key Information – Gilead Sciences, Inc.
TABLE 271 Key Information – Seagen Inc.
TABLE 272 Key Information – ADC Therapeutics SA
TABLE 273 Key Information – Daiichi Sankyo Company, Limited

List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players
FIG 5 Global Antibody Drug Conjugates Market Share by Application, 2021
FIG 6 Global Antibody Drug Conjugates Market Share by Application, 2028
FIG 7 Global Antibody Drug Conjugates Market by Application, 2018 - 2028, USD Million
FIG 8 Global Antibody Drug Conjugates Market Share by Technology, 2021
FIG 9 Global Antibody Drug Conjugates Market Share by Technology, 2028
FIG 10 Global Antibody Drug Conjugates Market by Technology, 2018 - 2028, USD Million
FIG 11 Global Antibody Drug Conjugates Market Share by Region, 2021
FIG 12 Global Antibody Drug Conjugates Market Share by Region, 2028
FIG 13 Global Antibody Drug Conjugates Market by Region, 2018- 2028, USD Million
FIG 14 Recent strategies and developments: Takeda Pharmaceutical Company Limited
FIG 15 Recent strategies and developments: Gilead Sciences, Inc.